Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT + Bevacizumab in EGFR-mutant NSCLC with Brain Metastases
NCT07197008Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07197008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197008.